臺灣博碩士論文加值系統

鐘擺式化療，又稱為節拍器式化學治療，是一種不同於以往傳統最大耐受劑量的化療方式，以低劑量、定期、很短的時間內重複的給藥，有如鐘擺的規律。此治療方式被認為是以腫瘤新生血管內皮為標的，即對附近供給腫瘤營養的新生血管造成抑制，使腫瘤無法得到營養達到縮小或減緩生長的效果，而且具有專一性，對正常組織較不具傷害性。以此篇研究目的為評估以合併低劑量3-4 mg/m2 chlorambucil與標準劑量0.3mg/kg piroxicam的治療策略，在犬隻癌症上的治療成效與毒性評估，並同時檢測血液中調節型T細胞的量評估調節型T細胞在鐘擺治療中扮演的腳色。
共21隻患犬納入本次研究，平均中位無病時間為140天，平均中位存活時間為261天。在有巨觀腫瘤在身上的患犬，整體有效率約20%，而約有一半的患犬能夠維持在穩定病程。研究發現，當身上沒有巨觀腫瘤的病患、治療前沒有遠端轉移、較低的臨床分級都有明顯延長的存活時間。就毒性而言，有38%的患犬有出現與治療相關的副作用，大部分都局限在輕微的腸胃道症狀如噁心、嘔吐、下痢，症狀多可自行緩解不需額外治療，有一隻患犬治療過程中出現血中肌酐酸(Creatinine)濃度上升的現象，當給藥頻率延長至兩天一次便能回復到正常。在調節型T細胞的平均百分比與總數中，發現在治療有效或穩定的患犬，在28天的序列測量中可以發現明顯的降低趨勢，代表鐘擺治療確實能夠透過調節免疫來達到抑制腫瘤的效果。
總體而言，鐘擺式chlorambucil與piroxicam的合併治療，對於多種的犬隻癌症有不錯的抗癌效果而且沒有嚴重副作用，而對於微觀腫瘤的病患，鐘擺治療更可以提供不錯的治療效果，相較於巨觀腫瘤，鐘擺式治療以維持病患生活品質與減緩腫瘤生長為主要目的。

Metronomic chemotherapy, the low-dose, frequently administered chemotherapy has revealed an important impact on the stabilization of cancer disease. Metronomic chemotherapy has revealed recently as an alternative treatment protocol to slow down cancer progression by its known antiangiogenic effect and modulation of immune status without severe adverse effects. The aim of this study was to evaluate the treatment outcome, tolerability and safety of a combination low-dose chlorambucil at a dosage of 3-4 mg/m2 daily and standard-dose piroxicam at a dosage of 0.3mg/kg in spontaneous canine cancers. In addition, the effects of Treg percentages of peripheral blood had been test to determine the function of immune modulation. 21 dogs were enrolled in the study. The median progression-free interval and the median survival time were 140 days and 261 days. In macroscopic disease dogs, overall remission rate was 20% (two of 10). SD was noted in five of 10 dogs (50%). Microscopic disease, without metastasis at the presentation and low to intermediated clinical stage had a significant longer survival time. All the side effects mostly limited to the grade I-II gastrointestinal signs (anorexia, nausea/vomiting or diarrhea) without any hematological or urological toxicity. Only one dog (5%) had elevated creatinine level during treatment. The protocol was well tolerated without severe adverse effects. By series examination of Treg level, there were significant decreasing in mean percentage and absolute number of regulatory T cell of the 28 -day period for the response or stable dogs.
In this study, metronomic chlorambucil with piroxicam revealed an acceptable antitumor effect in many kind of canine cancer without severe adverse effect.

誌謝 I
中文摘要 II
Abstract III
Content V
Table contents VII
Figure contents VIII
Chapter I Introduction 1
1.1. The background of metronomic therapy 1
1.2. Tumor angiogenesis 2
1.3. The mechanism of metronomic therapy 4
1.4. Regulatory T cell 5
1.5. Chlorambucil 6
1.6. Piroxicam 7
Chapter II Literatures review 9
2.1. The efficacy of previous studies of metronomic therapy in canine cancer 9
2.2. Adverse events of metronomic therapy 11
2.3. The effect of metronomic therapy in immune modulation 12
Chapter III Aim 15
Chapter IV Materials and methods 16
4.1. Study population 16
4.2. Study design 17
4.3. Response evaluation 18
4.4. Toxicity 19
4.5. Regulatory T cell 19
4.6. Statistical analysis 20
Chapter V Result 22
5.1. Patient characteristics 22
5.2. Tumor response 24
5.3. Analysis of progression free interval in treatment group 24
5.4. Analysis of overall survival time in treatment group 25
5.5. Comparison of PFI in control versus treated dogs 26
5.6. Comparison of OST in control versus treated dogs 26
5.7. Toxicity 28
5.8. Regulatory T cell 29
Chapter VI Discussion 30
6.1. Treatment outcome 30
6.3. Dose of chlorambucil 35
6.4. Toxicity 36
6.5. Regulatory T cell 37
6.6. Limitation of this study 39
Chapter VII Conclusion 41
Tables and Figures 43
References 71

Argyle DJ, Khanna C. Tumor biology and metastasus. In: Withrow SJ, Vail DM, Page RL, ed. Withrow and MacEwen''s small animal clinical oncology. 5th ed. Saunders, Missouri, 43-44, 2013.
Baecher-Allan C, and Anderson DE. Regulatory cells and human cancer. In: Seminars in cancer biologyElsevier, 2006, p. 98-105.
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, and Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer research 63: 4342-4346, 2003.
Biller BJ, Elmslie RE, Burnett RC, Avery AC, and Dow SW. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Veterinary immunology and immunopathology 116: 69-78, 2007.
Biller BJ, Guth A, Burton JH, and Dow SW. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 24: 1118-1123, 2010.
Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O''Reilly MS, and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer research 60: 1878-1886, 2000.
Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, and Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Exs 79: 233-269, 1997.
Burton JH, Mitchell L, Thamm DH, Dow SW, and Biller BJ. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 25: 920-926, 2011.
Davidson GSBRFD. Compounding Antiangiogenic Cancer Therapy for Animals. International journal of pharmaceutical compounding 9: 195-198, 2005.
Elmslie RE, Glawe P, and Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 22: 1373-1379, 2008.
Faldyna M, Leva L, Knotigova P, and Toman M. Lymphocyte subsets in peripheral blood of dogs--a flow cytometric study. Veterinary immunology and immunopathology 82: 23-37, 2001.
Folkman J. Tumor angiogenesis: therapeutic implications. The New England journal of medicine 285: 1182-1186, 1971.
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, and Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer immunology, immunotherapy : CII 56: 641-648, 2007.
Gustafson DL, Page RL. Cancer chemotherapy. In: Withrow SJ, Vail DM, Page RL ed. Withrow and MacEwen''s small animal clinical oncology. 5th ed. Saunders, Missouri, 165-167, 2013.
Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, and Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer research 64: 1570-1574, 2004.
Hanahan D, Bergers G, and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. The Journal of clinical investigation 105: 1045-1047, 2000.
Horiuchi Y, Tominaga M, Ichikawa M, Yamashita M, Okano K, Jikumaru Y, Nariai Y, Nakajima Y, Kuwabara M, and Yukawa M. Relationship between regulatory and type 1 T cells in dogs with oral malignant melanoma. Microbiology and immunology 54: 152-159, 2010.
Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
Kerbel RS, and Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nature reviews Cancer 4: 423-436, 2004.
Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, and Fujii H. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer immunology, immunotherapy : CII 55: 1064-1071, 2006.
Lana S, U''Ren L, Plaza S, Elmslie R, Gustafson D, Morley P, and Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 21: 764-769, 2007.
Leach TN, Childress MO, Greene SN, Mohamed AS, Moore GE, Schrempp DR, Lahrman SR, and Knapp DW. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. Veterinary and comparative oncology 10: 102-112, 2012.
Leo C, Stell A, Borrego J, Martinez de Merlo E, Ruess-Melzer K, and Lara-Garcia A. Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia. Journal of feline medicine and surgery 16: 671-678, 2014.
Lutsiak MC, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, and Sabzevari H. Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868, 2005.
Marchetti V, Giorgi M, Fioravanti A, Finotello R, Citi S, Canu B, Orlandi P, Di Desidero T, Danesi R, and Bocci G. First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Investigational new drugs 30: 1725-1730, 2012.
Matar P, Rozados VR, Gonzalez AD, Dlugovitzky DG, Bonfil RD, and Scharovsky OG. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. European journal of cancer (Oxford, England : 1990) 36: 1060-1066, 2000.
Mitchell L, Thamm DH, and Biller BJ. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 26: 355-362, 2012.
Mohammed SI, Craig BA, Mutsaers AJ, Glickman NW, Snyder PW, deGortari AE, Schlittler DL, Coffman KT, Bonney PL, and Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Molecular cancer therapeutics 2: 183-188, 2003.
Mougiakakos D, Choudhury A, Lladser A, Kiessling R, and Johansson CC. Regulatory T cells in cancer. Advances in cancer research 107: 57-117, 2010.
Mross K, and Steinbild S. Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients. journal of Cancer Therapeutics and Research 1: 32, 2012.
Mutsaers AJ, Mohammed SI, DeNicola DB, et al. Metronomic chemotherapy in veterinary oncology, a pilot study [abstract]. Proceedings of the 21st Veterinary Cancer Society Conference, 2001
Mutsaers AJ. Metronomic chemotherapy. Topics in companion animal medicine 24: 137-143, 2009.
Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, and Cebon J. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 15: 2166-2173, 2009.
O''Neill K, Guth A, Biller B, Elmslie R, and Dow S. Changes in regulatory T cells in dogs with cancer and associations with tumor type. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 23: 875-881, 2009.
Owen LN. TNM classification of tumours in domestic animals. World Health Organization. Veterinary Public Health Unit, 1980.
Plumb DC. Chlorambucil. In: Plumb DC ed. Plumb’s veterinary drug hand book. 7th ed. Wiley-Blackwell, Iowa, 263-266, 2011.
Plumb DC. Cyclophosphamide. In: Plumb DC ed. Plumb’s veterinary drug hand book. 7th ed. Wiely-Blackwell, Iowa, 348-352, 2011.
Plumb DC. Piroxicam. In: Plumb DC ed. Plumb’s veterinary drug hand book. 7th ed. Wiely-Blackwell, Iowa, 1121-1124, 2011.
Queiroga FL, Pires I, Parente M, Gregorio H, and Lopes CS. COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. Veterinary journal (London, England : 1997) 189: 77-82, 2011.
Richardson MR, and Yoder MC. Endothelial progenitor cells: quo vadis? Journal of molecular and cellular cardiology 50: 266-272, 2011.
Scharovsky OG, Mainetti LE, and Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Current oncology (Toronto, Ont) 16: 7-15, 2009.
Schrempp DR, Childress MO, Stewart JC, Leach TN, Tan KM, Abbo AH, de Gortari AE, Bonney PL, and Knapp DW. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. Journal of the American Veterinary Medical Association 242: 1534-1538, 2013.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92: 205-216, 2000.
Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Veterinary and comparative oncology 2011.
Wilke CM, Wu K, Zhao E, Wang G, and Zou W. Prognostic significance of regulatory T cells in tumor. International journal of cancer Journal international du cancer 127: 748-758, 2010.